Smith & Nephew PLC
NPW1
Company Profile
Business description
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
Contact
Hatters Lane
Building 5, Croxley Park
WatfordHertfordshireWD18 8YE
GBRT: +44 1923477100
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
17,000
Stocks News & Analysis
stocks
Samsung and SK Hynix lead chip selloff as China competition fears grow
CXMT’s claimed tech breakthrough and an AI industry leader’s comments are weighing on stocks across the sector.
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Stronger copper, aluminum and zinc prices offset by iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.30 | 70.20 | -0.79% |
| CAC 40 | 7,827.63 | 5.25 | -0.07% |
| DAX 40 | 25,259.90 | 17.78 | -0.07% |
| Dow JONES (US) | 51,670.10 | 180.45 | -0.35% |
| FTSE 100 | 10,650.33 | 5.95 | -0.06% |
| HKSE | 24,414.55 | 69.33 | 0.28% |
| NASDAQ | 27,204.38 | 41.52 | -0.15% |
| Nikkei 225 | 68,193.13 | 415.61 | 0.61% |
| NZX 50 Index | 13,753.68 | 4.08 | 0.03% |
| S&P 500 | 7,805.45 | 1.79 | -0.02% |
| S&P/ASX 200 | 8,708.10 | 75.80 | -0.86% |
| SSE Composite Index | 3,803.22 | 2.35 | 0.06% |